Covered recipient · General Payments record
ASHOK PATEL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$22,723.92
31 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,594.40 | 8 |
| Consulting Fee | $4,810.00 | 1 |
| Travel and Lodging | $1,571.48 | 4 |
| Food and Beverage | $748.04 | 18 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $17,685.32 | 23 |
| Eisai Inc. | $4,810.00 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $95.96 | 1 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $63.95 | 2 |
| ABBVIE INC. | $33.95 | 2 |
| Lilly USA, LLC | $21.44 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.30 | 1 |
Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ASHOK PATEL
NPI 1093809576 · CMS profile ID 276954
TOMS RIVER, NJ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1093809576?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093809576?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093809576?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ASHOK PATEL, NPI 1093809576, CMS profile ID 276954, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1093809576?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
31 matching records · $22,723.92 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–31 of 31.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $2,106.00 | 12/18/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957692 | CMS |
| Otsuka America Pharmaceutical, Inc. | $2,106.00 | 12/13/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957690 | CMS |
| Otsuka America Pharmaceutical, Inc. | $20.45 | 12/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957688 | CMS |
| ABBVIE INC. | $16.10 | 11/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105191409 | CMS |
| Lilly USA, LLC | $21.44 | 11/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136060166 | CMS |
| Otsuka America Pharmaceutical, Inc. | $351.00 | 10/26/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957686 | CMS |
| Otsuka America Pharmaceutical, Inc. | $19.49 | 09/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957682 | CMS |
| Otsuka America Pharmaceutical, Inc. | $8.64 | 09/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957684 | CMS |
| Otsuka America Pharmaceutical, Inc. | $2,106.00 | 09/18/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957680 | CMS |
| Otsuka America Pharmaceutical, Inc. | $21.48 | 09/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957678 | CMS |
| Eisai Inc. | $4,810.00 | 07/25/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110731997 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.30 | 06/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137649654 | CMS |
| ABBVIE INC. | $17.85 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105191407 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $95.96 | 05/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117871226 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $26.45 | 05/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118838933 | CMS |
| Otsuka America Pharmaceutical, Inc. | $3,790.00 | 05/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957676 | CMS |
| Otsuka America Pharmaceutical, Inc. | $2,106.00 | 04/26/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957674 | CMS |
| Otsuka America Pharmaceutical, Inc. | $27.21 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957672 | CMS |
| Otsuka America Pharmaceutical, Inc. | $59.54 | 04/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957666 | CMS |
| Otsuka America Pharmaceutical, Inc. | $28.00 | 04/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957668 | CMS |
| Otsuka America Pharmaceutical, Inc. | $53.01 | 04/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957670 | CMS |
| Otsuka America Pharmaceutical, Inc. | $131.46 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957664 | CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $37.50 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118838931 | CMS |
| Otsuka America Pharmaceutical, Inc. | $587.96 | 04/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957656 | CMS |
| Otsuka America Pharmaceutical, Inc. | $669.07 | 04/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957658 | CMS |
| Otsuka America Pharmaceutical, Inc. | $204.45 | 04/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957660 | CMS |
| Otsuka America Pharmaceutical, Inc. | $110.00 | 04/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957662 | CMS |
| Otsuka America Pharmaceutical, Inc. | $25.16 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957654 | CMS |
| Otsuka America Pharmaceutical, Inc. | $923.40 | 03/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957652 | CMS |
| Otsuka America Pharmaceutical, Inc. | $2,106.00 | 02/29/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957650 | CMS |
| Otsuka America Pharmaceutical, Inc. | $125.00 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118957648 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,752.51 | 11 |
| PY2025 | Principal investigator | $1,229,009.00 | 130 |
| PY2024 | Principal investigator | $3,194,861.98 | 28 |
| PY2023 | Recipient | $355.00 | 1 |
| PY2023 | Principal investigator | $1,914,939.19 | 59 |
| PY2022 | Recipient | $1,248.00 | 4 |
| PY2022 | Principal investigator | $1,105,512.02 | 75 |
| PY2021 | Recipient | $13,374.00 | 3 |
| PY2021 | Principal investigator | $1,695,784.21 | 81 |
| PY2020 | Recipient | $6,288.97 | 21 |
| PY2020 | Principal investigator | $1,118,610.73 | 104 |
| PY2019 | Recipient | $18,854.85 | 12 |
| PY2019 | Principal investigator | $1,138,230.38 | 171 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
125 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Allergan, Inc. | $5,642.16 | 12/31/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330419 |
| Principal investigator 1 | Allergan, Inc. | $250.00 | 12/31/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330421 |
| Principal investigator 1 | Allergan, Inc. | $2,951.36 | 12/31/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721330423 |
| Principal investigator 1 | Allergan, Inc. | $694.50 | 12/31/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330425 |
| Principal investigator 1 | Allergan, Inc. | $3,436.23 | 12/31/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 721330427 |
| Principal investigator 1 | Amgen Inc. | $907.86 | 12/28/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | Work Productivity Study | No dispute reported | 06/30/2026 | 753889395 |
| Principal investigator 1 | Eli Lilly and Company | $18,400.00 | 12/28/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE | No dispute reported | 06/30/2026 | 728731991 |
| Principal investigator 1 | Allergan, Inc. | $24,602.15 | 12/23/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 721330417 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $3,532.81 | 12/21/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | ACP-103-063 | No dispute reported | 06/30/2026 | 748385291 |
| Principal investigator 1 | Eisai Inc. | $12,951.00 | 12/21/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102483 |
| Principal investigator 1 | Allergan, Inc. | $5,334.25 | 12/15/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721330413 |
| Principal investigator 1 | Allergan, Inc. | $1,476.30 | 12/15/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330415 |
| Principal investigator 1 | Allergan, Inc. | $552.00 | 12/08/2020 | Non-covered Recipient Entity BIOLOGY BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330411 |
| Principal investigator 1 | Eisai Inc. | $19,872.00 | 12/08/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102465 |
| Principal investigator 1 | Eisai Inc. | $5,312.18 | 12/08/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102467 |
| Principal investigator 1 | Eisai Inc. | $2,570.79 | 12/08/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102471 |
| Principal investigator 1 | ITI, Inc. | $12,487.40 | 12/04/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) | No dispute reported | 06/30/2026 | 750026701 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $16,451.50 | 12/03/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A randomized, double-blind, placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder | No dispute reported | 06/30/2026 | 748986373 |
| Principal investigator 1 | Allergan, Inc. | $5,602.15 | 11/23/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 721330409 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $10,282.23 | 11/20/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | ACP-103-063 | No dispute reported | 06/30/2026 | 748385139 |
| Principal investigator 1 | Allergan, Inc. | $9,533.25 | 11/19/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721330407 |
| Principal investigator 1 | Allergan, Inc. | $1,886.70 | 11/16/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330405 |
| Principal investigator 1 | Amgen Inc. | $1,210.48 | 11/09/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | Work Productivity Study | No dispute reported | 06/30/2026 | 753889379 |
| Principal investigator 1 | Eli Lilly and Company | $646.19 | 11/09/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE | No dispute reported | 06/30/2026 | 728732507 |
| Principal investigator 1 | Allergan, Inc. | $29,412.00 | 10/23/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 721330403 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $1,901.12 | 10/20/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | ACP-103-063 | No dispute reported | 06/30/2026 | 748384999 |
| Principal investigator 1 | Allergan, Inc. | $327.00 | 10/20/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721304289 |
| Principal investigator 1 | Allergan, Inc. | $2,500.00 | 10/15/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 721330397 |
| Principal investigator 1 | Allergan, Inc. | $2,500.00 | 10/15/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 721330399 |
| Principal investigator 1 | Allergan, Inc. | $10,000.00 | 10/15/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE | No dispute reported | 06/30/2026 | 721330401 |
| Principal investigator 1 | Eisai Inc. | $35,233.20 | 10/15/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102489 |
| Principal investigator 1 | Allergan, Inc. | $1,928.50 | 10/14/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330395 |
| Recipient | Eli Lilly and Company | $50.00 | 09/30/2020 | Covered Recipient Physician | A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 728716461 |
| Principal investigator 1 | Eisai Inc. | $20,157.00 | 09/21/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102493 |
| Principal investigator 1 | Allergan, Inc. | $3,505.50 | 09/15/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330393 |
| Principal investigator 1 | Allergan, Inc. | $700.00 | 09/10/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721296423 |
| Principal investigator 1 | Allergan, Inc. | $4,761.20 | 09/07/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330391 |
| Recipient | Eli Lilly and Company | $100.00 | 08/31/2020 | Covered Recipient Physician | A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | No dispute reported | 06/30/2026 | 728717747 |
| Principal investigator 1 | Allergan, Inc. | $1,170.30 | 08/24/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330389 |
| Principal investigator 1 | Allergan, Inc. | $276.00 | 08/21/2020 | Non-covered Recipient Entity BIOLOGY BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330387 |
| Principal investigator 1 | Eisai Inc. | $7,901.10 | 08/19/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102487 |
| Principal investigator 1 | Allergan, Inc. | $6,481.85 | 08/13/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330385 |
| Recipient | Eli Lilly and Company | $130.00 | 08/10/2020 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 728717151 |
| Recipient | Eli Lilly and Company | $76.50 | 08/10/2020 | Covered Recipient Physician | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 728717517 |
| Principal investigator 1 | Allergan, Inc. | $6,565.45 | 08/07/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330383 |
| Principal investigator 1 | Eisai Inc. | $1,321.20 | 08/05/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102469 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 07/30/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721287755 |
| Principal investigator 1 | Allergan, Inc. | $700.00 | 07/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721287341 |
| Principal investigator 1 | Eisai Inc. | $8,796.60 | 07/20/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102463 |
| Principal investigator 1 | Eisai Inc. | $2,985.00 | 07/16/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749101951 |
| Principal investigator 1 | Eisai Inc. | $2,985.00 | 07/16/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749101953 |
| Principal investigator 1 | Eisai Inc. | $2,985.00 | 07/16/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749101955 |
| Principal investigator 1 | Eisai Inc. | $25,720.40 | 07/16/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102313 |
| Principal investigator 1 | Eisai Inc. | $245.10 | 07/16/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102319 |
| Principal investigator 1 | Allergan, Inc. | $7,501.15 | 07/14/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330381 |
| Principal investigator 1 | Eisai Inc. | $3,000.00 | 07/09/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 749102485 |
| Principal investigator 1 | Allergan, Inc. | $5,775.05 | 06/16/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330379 |
| Principal investigator 1 | Allergan, Inc. | $2,362.65 | 05/20/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330377 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,529.30 | 05/20/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A 12-WEEK, MULTICENTER, ACTIVE-TREATMENT EXTENSION TRIAL TO EVAULATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | No dispute reported | 06/30/2026 | 748804803 |
| Principal investigator 1 | Allergan, Inc. | $1,360.40 | 05/14/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330375 |
| Principal investigator 1 | Allergan, Inc. | $4,881.10 | 05/13/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330373 |
| Principal investigator 1 | Allergan, Inc. | $660.00 | 05/12/2020 | Non-covered Recipient Entity BIOLOGY BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330371 |
| Principal investigator 1 | Eisai Inc. | $691.20 | 05/12/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia | No dispute reported | 06/30/2026 | 749101941 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $1,443.08 | 05/05/2020 | Non-covered Recipient Entity BIOBEHAVIORAL HEALTH | ACP-103-063 | No dispute reported | 06/30/2026 | 748383087 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $10,382.55 | 04/29/2020 | Non-covered Recipient Entity VANTAGE CLINICAL TRIALS | 18-AVP-786-207 | No dispute reported | 06/30/2026 | 722220611 |
| Principal investigator 1 | Allergan, Inc. | $5,857.70 | 04/17/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330369 |
| Principal investigator 1 | Allergan, Inc. | $4,989.40 | 04/14/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330365 |
| Principal investigator 1 | Allergan, Inc. | $3,108.40 | 04/14/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330367 |
| Recipient | Eli Lilly and Company | $4,193.00 | 04/07/2020 | Covered Recipient Physician | EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | No dispute reported | 06/30/2026 | 728717515 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $17,677.40 | 04/06/2020 | Non-covered Recipient Entity BIOBEHAVIORAL HEALTH | ACP-103-045 | No dispute reported | 06/30/2026 | 748382277 |
| Principal investigator 1 | Amgen Inc. | $17,009.30 | 03/20/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | Work Productivity Study | No dispute reported | 06/30/2026 | 731645917 |
| Principal investigator 1 | Allergan, Inc. | $6,844.75 | 03/19/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330363 |
| Principal investigator 1 | Allergan, Inc. | $9,059.20 | 03/16/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330361 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $19,424.10 | 03/14/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | ACP-103-048 | No dispute reported | 06/30/2026 | 748381775 |
| Principal investigator 1 | Allergan, Inc. | $5,568.90 | 03/13/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330359 |
| Principal investigator 1 | Allergan, Inc. | $327.00 | 03/12/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721263525 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $32,310.51 | 03/11/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE (OPC34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | No dispute reported | 06/30/2026 | 748804141 |
| Principal investigator 1 | Allergan, Inc. | $6,052.00 | 03/01/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330357 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $10,500.00 | 02/25/2020 | Non-covered Recipient Entity BIOBEHAVIORAL HEALTH | ACP-103-063 | No dispute reported | 06/30/2026 | 748381559 |
| Principal investigator 1 | Allergan, Inc. | $7,776.70 | 02/24/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330353 |
| Principal investigator 1 | Allergan, Inc. | $11,502.60 | 02/24/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721330355 |
| Principal investigator 1 | Amgen Inc. | $14,891.30 | 02/22/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | Work Productivity Study | No dispute reported | 06/30/2026 | 731645927 |
| Principal investigator 1 | Allergan, Inc. | $11,151.10 | 02/14/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330351 |
| Principal investigator 1 | Allergan, Inc. | $2,236.30 | 02/13/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330349 |
| Principal investigator 1 | Amgen Inc. | $97.97 | 02/10/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | Work Productivity Study | No dispute reported | 06/30/2026 | 731645935 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $170.00 | 02/06/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH PC | ACP-103-056 | No dispute reported | 06/30/2026 | 748381385 |
| Principal investigator 1 | Amgen Inc. | $13,341.00 | 01/30/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | Work Productivity Study | No dispute reported | 06/30/2026 | 731645931 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $4,000.00 | 01/29/2020 | Non-covered Recipient Entity BIOBEHAVIORAL HEALTH | 17-AVP-786-305 | No dispute reported | 06/30/2026 | 722219423 |
| Principal investigator 1 | Allergan, Inc. | $385.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721252339 |
| Principal investigator 1 | Allergan, Inc. | $225.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD). | No dispute reported | 06/30/2026 | 721253539 |
| Recipient | ACADIA Pharmaceuticals Inc | $104.65 | 01/26/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379921 |
| Recipient | ACADIA Pharmaceuticals Inc | $19.50 | 01/25/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379907 |
| Recipient | ACADIA Pharmaceuticals Inc | $43.21 | 01/25/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379911 |
| Recipient | ACADIA Pharmaceuticals Inc | $7.39 | 01/25/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379915 |
| Recipient | ACADIA Pharmaceuticals Inc | $38.65 | 01/25/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379917 |
| Recipient | ACADIA Pharmaceuticals Inc | $63.15 | 01/24/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379889 |
| Recipient | ACADIA Pharmaceuticals Inc | $41.89 | 01/24/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379893 |
| Recipient | ACADIA Pharmaceuticals Inc | $50.86 | 01/24/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379895 |
| Recipient | ACADIA Pharmaceuticals Inc | $20.39 | 01/24/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379899 |
| Recipient | ACADIA Pharmaceuticals Inc | $75.56 | 01/24/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379901 |
| Recipient | ACADIA Pharmaceuticals Inc | $17.44 | 01/24/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379905 |
| Recipient | ACADIA Pharmaceuticals Inc | $49.00 | 01/23/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379875 |
| Recipient | ACADIA Pharmaceuticals Inc | $63.40 | 01/23/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379879 |
| Recipient | ACADIA Pharmaceuticals Inc | $542.26 | 01/23/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379883 |
| Recipient | ACADIA Pharmaceuticals Inc | $172.33 | 01/23/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379885 |
| Principal investigator 1 | Avanir Pharmaceuticals, Inc. | $1,198.50 | 01/23/2020 | Non-covered Recipient Entity BIOBEHAVIORAL HEALTH | 15-AVP-786-303 | No dispute reported | 06/30/2026 | 722219421 |
| Principal investigator 1 | Allergan, Inc. | $4,290.20 | 01/22/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330345 |
| Principal investigator 1 | Allergan, Inc. | $11,867.40 | 01/22/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721330347 |
| Principal investigator 1 | Genentech, Inc. | $17,735.50 | 01/21/2020 | Non-covered Recipient Entity BIO BEHAVIORHAL HEALTH | GTP1 PHASE I LONGITUDINAL STUDY | No dispute reported | 06/30/2026 | 743035619 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $222,757.30 | 01/21/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | No dispute reported | 06/30/2026 | 748803579 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $3,237.89 | 01/20/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH PC | ACP-103-056 | No dispute reported | 06/30/2026 | 748381097 |
| Principal investigator 1 | Eli Lilly and Company | $4,257.50 | 01/16/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR | No dispute reported | 06/30/2026 | 728732509 |
| Principal investigator 1 | Allergan, Inc. | $3,086.55 | 01/15/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE | No dispute reported | 06/30/2026 | 721330343 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 01/14/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721246763 |
| Principal investigator 1 | Allergan, Inc. | $2,000.00 | 01/14/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330339 |
| Principal investigator 1 | Allergan, Inc. | $12,200.85 | 01/14/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330341 |
| Principal investigator 1 | Eli Lilly and Company | $3,801.90 | 01/09/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | No dispute reported | 06/30/2026 | 728731161 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $101,724.71 | 01/09/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | No dispute reported | 06/30/2026 | 748802889 |
| Recipient | ACADIA Pharmaceuticals Inc | $429.79 | 01/07/2020 | Covered Recipient Physician | ACP-103-063 | No dispute reported | 06/30/2026 | 748379873 |
| Principal investigator 1 | Eli Lilly and Company | $119,542.59 | 01/07/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | No dispute reported | 06/30/2026 | 728731101 |
| Principal investigator 1 | Allergan, Inc. | $737.53 | 01/03/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 721330337 |
| Principal investigator 1 | Amgen Inc. | $16,817.28 | 01/03/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | Work Productivity Study | No dispute reported | 06/30/2026 | 731645923 |
| Principal investigator 1 | Allergan, Inc. | $113.93 | 01/01/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721330331 |
| Principal investigator 1 | Allergan, Inc. | $126.55 | 01/01/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721330333 |
| Principal investigator 1 | Allergan, Inc. | $206.43 | 01/01/2020 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 721330335 |